Prof. Dr. Alexander Hillisch: Design of BAY224, a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral Pharmacokinetics

16.10.2017 | 14:00 s.t.


Dieser Vortrag findet im Rahmen des pharmazeutischen Forschungskolloquiums statt.

Zeit & Ort

16.10.2017 | 14:00 s.t.

Institut für Pharmazie, Hörsaal 1. Stock, Königin-Luise-Straße 2+4, 14195 Berlin-Dahlem

Weitere Informationen

Prof. Alexander Hillisch is a Director of Medicinal Chemistry and Head of Computational Chemistry at Bayer AG, Wuppertal, Germany. His team supports drug discovery efforts in cardiology and ophthalmology indication areas with computational chemistry, chemoinformatics, in silico ADMET and structural bioinformatics techniques. From 1998 to 2003 he headed a research group at EnTec GmbH, Jena, Germany, a subsidiary of Schering AG, Berlin. There he was project manager in preclinical research and involved in the computer-aided design and pharmacological characterization of drugs against gynecological diseases and cancer. He conducted his Ph.D. thesis at the Institute of Molecular Biotechnology (IMB), Jena in the area of biophysics (NMR, FRET) and molecular modeling. Alexander Hillisch received his Ph.D. in Biochemistry with Prof. Peter Schuster in 1998 and his diploma in Pharmacy in 1995 from the University of Vienna, Austria. He is author of 42 research papers, 59 patents and 2 books. Prof. Hillisch teaches “Molecular pharmacology and Drug Design” at the University of Cologne from which he received a honorary professorship in 2010.